BRPI0621074B1 - método de inativação viral através de aquecimento a seco - Google Patents
método de inativação viral através de aquecimento a secoInfo
- Publication number
- BRPI0621074B1 BRPI0621074B1 BRPI0621074A BRPI0621074A BRPI0621074B1 BR PI0621074 B1 BRPI0621074 B1 BR PI0621074B1 BR PI0621074 A BRPI0621074 A BR PI0621074A BR PI0621074 A BRPI0621074 A BR PI0621074A BR PI0621074 B1 BRPI0621074 B1 BR PI0621074B1
- Authority
- BR
- Brazil
- Prior art keywords
- biological product
- dry
- product
- glass transition
- temperature
- Prior art date
Links
- 230000002779 inactivation Effects 0.000 title claims abstract description 62
- 230000003612 virological effect Effects 0.000 title claims abstract description 57
- 238000010438 heat treatment Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000009477 glass transition Effects 0.000 claims abstract description 35
- 241000700605 Viruses Species 0.000 claims abstract description 20
- 230000009467 reduction Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 244000309711 non-enveloped viruses Species 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 65
- 241000709721 Hepatovirus A Species 0.000 description 14
- 241000702619 Porcine parvovirus Species 0.000 description 13
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 9
- 241000035705 Enterobacteria phage PR772 Species 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108010054218 Factor VIII Proteins 0.000 description 8
- 102000001690 Factor VIII Human genes 0.000 description 8
- 229960000301 factor viii Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 108010047303 von Willebrand Factor Proteins 0.000 description 6
- 102100036537 von Willebrand factor Human genes 0.000 description 6
- 229960001134 von willebrand factor Drugs 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000011109 contamination Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005373 pervaporation Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- -1 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0512875A FR2894830B1 (fr) | 2005-12-19 | 2005-12-19 | Procede d'inactivation virale par chauffage a sec selon la temperature de transition vitreuse |
| FR0512875 | 2005-12-19 | ||
| PCT/FR2006/002817 WO2007071845A2 (fr) | 2005-12-19 | 2006-12-19 | Procede d'inactivation virale par chauffage a sec selon la temperature de transition vitreuse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0621074A2 BRPI0621074A2 (pt) | 2011-11-29 |
| BRPI0621074B1 true BRPI0621074B1 (pt) | 2016-07-26 |
Family
ID=36698885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0621074A BRPI0621074B1 (pt) | 2005-12-19 | 2006-12-19 | método de inativação viral através de aquecimento a seco |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8252227B2 (enExample) |
| EP (1) | EP1981549B1 (enExample) |
| JP (1) | JP5085558B2 (enExample) |
| KR (1) | KR101162060B1 (enExample) |
| CN (1) | CN101355972B (enExample) |
| AT (1) | ATE431162T1 (enExample) |
| AU (1) | AU2006328804B2 (enExample) |
| BR (1) | BRPI0621074B1 (enExample) |
| CA (1) | CA2633338C (enExample) |
| DE (1) | DE602006006875D1 (enExample) |
| DK (1) | DK1981549T3 (enExample) |
| ES (1) | ES2327279T3 (enExample) |
| FR (1) | FR2894830B1 (enExample) |
| IL (1) | IL192194A (enExample) |
| PL (1) | PL1981549T3 (enExample) |
| WO (1) | WO2007071845A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501365A1 (en) | 2010-12-30 | 2013-09-16 | Laboratoire Francais Du Fractionnment Et Des Biotechnologies | Glycols as pathogen inactivating agents |
| USD689039S1 (en) * | 2012-07-12 | 2013-09-03 | Alljack Co., Ltd. | Stereo set |
| CN109444209A (zh) * | 2018-10-26 | 2019-03-08 | 北京食品科学研究院 | 一种测量蛋清粉玻璃化转变温度的方法 |
| CN116059410A (zh) * | 2021-08-19 | 2023-05-05 | 南京金斯瑞生物科技有限公司 | 一种去除生物样本中噬菌体的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248817C2 (de) * | 1972-10-05 | 1981-09-24 | Bayer Ag, 5090 Leverkusen | Polycarbonatmischungen |
| US4456590B2 (en) * | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
| GB9424732D0 (en) * | 1994-12-08 | 1995-02-08 | Common Services Agency | Heat treated blood plasma proteins |
| US5837519A (en) * | 1996-11-21 | 1998-11-17 | Bayer Corporation | Dry-heat viral inactivation under controlled moisture conditions |
| ATE429491T1 (de) * | 1997-09-23 | 2009-05-15 | Ib2 L L C | Verfahren und vorrichtung für schnelle thermozyklen |
| CN1286725A (zh) * | 1997-11-26 | 2001-03-07 | 环球保藏技术股份有限公司 | 敏感性生物样品的玻化保质法 |
| DK1121015T4 (da) * | 1998-10-14 | 2012-05-21 | Katrina T Forest | Fremgangsmåde til forglasning af et biologisk materiale |
| WO2001049112A2 (en) * | 2000-01-04 | 2001-07-12 | University Of Connecticut | Oocyte vitrification technique |
| JP2007501224A (ja) * | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー．ブイ． | 安定剤としての組換え又は合成ゼラチン様タンパク質の、凍結乾燥医薬組成物中の使用 |
-
2005
- 2005-12-19 FR FR0512875A patent/FR2894830B1/fr not_active Expired - Lifetime
-
2006
- 2006-12-19 WO PCT/FR2006/002817 patent/WO2007071845A2/fr not_active Ceased
- 2006-12-19 CN CN2006800479202A patent/CN101355972B/zh active Active
- 2006-12-19 DK DK06847095T patent/DK1981549T3/da active
- 2006-12-19 CA CA2633338A patent/CA2633338C/en active Active
- 2006-12-19 BR BRPI0621074A patent/BRPI0621074B1/pt not_active IP Right Cessation
- 2006-12-19 ES ES06847095T patent/ES2327279T3/es active Active
- 2006-12-19 US US12/097,860 patent/US8252227B2/en active Active
- 2006-12-19 AT AT06847095T patent/ATE431162T1/de active
- 2006-12-19 JP JP2008545048A patent/JP5085558B2/ja not_active Expired - Fee Related
- 2006-12-19 AU AU2006328804A patent/AU2006328804B2/en not_active Ceased
- 2006-12-19 DE DE602006006875T patent/DE602006006875D1/de active Active
- 2006-12-19 PL PL06847095T patent/PL1981549T3/pl unknown
- 2006-12-19 KR KR1020087016839A patent/KR101162060B1/ko not_active Expired - Fee Related
- 2006-12-19 EP EP06847095A patent/EP1981549B1/fr active Active
-
2008
- 2008-06-15 IL IL192194A patent/IL192194A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL192194A0 (en) | 2009-02-11 |
| ES2327279T3 (es) | 2009-10-27 |
| WO2007071845A3 (fr) | 2007-08-16 |
| KR101162060B1 (ko) | 2012-07-03 |
| CN101355972A (zh) | 2009-01-28 |
| PL1981549T3 (pl) | 2009-10-30 |
| KR20080093098A (ko) | 2008-10-20 |
| WO2007071845A2 (fr) | 2007-06-28 |
| IL192194A (en) | 2010-12-30 |
| US8252227B2 (en) | 2012-08-28 |
| CA2633338A1 (en) | 2007-06-28 |
| FR2894830A1 (fr) | 2007-06-22 |
| EP1981549A2 (fr) | 2008-10-22 |
| ATE431162T1 (de) | 2009-05-15 |
| FR2894830B1 (fr) | 2008-04-04 |
| AU2006328804B2 (en) | 2012-08-02 |
| US20090297398A1 (en) | 2009-12-03 |
| CA2633338C (en) | 2012-02-28 |
| JP2009519920A (ja) | 2009-05-21 |
| CN101355972B (zh) | 2012-07-04 |
| DE602006006875D1 (de) | 2009-06-25 |
| EP1981549B1 (fr) | 2009-05-13 |
| BRPI0621074A2 (pt) | 2011-11-29 |
| DK1981549T3 (da) | 2009-08-17 |
| JP5085558B2 (ja) | 2012-11-28 |
| AU2006328804A1 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI98491C (fi) | Menetelmä virusinaktivoidun verituotteen valmistamiseksi | |
| JP2012051895A (ja) | ウイルス不活性化熱処理へ供するための血漿タンパク質の寒冷沈降物を安定化する方法 | |
| JP4278861B2 (ja) | ウイルス汚染に対する安全性の高いフィブリンのり形成用成分をヒト血漿プールから製造する方法 | |
| JP2007131638A (ja) | フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物 | |
| KR20150008848A (ko) | 건조된 생물학적 물질을 안정화시키는 방법 및 조성물 | |
| BR112016014870B1 (pt) | formulação de selante líquido compreendendo monômeros de fibrina e um peptídeo de gprp, seu método de fabricação, recipiente e kit | |
| CN102258770A (zh) | 一种安全高效的冻干纤维蛋白封闭剂及其制备方法 | |
| Cusinato et al. | Effectiveness of hydrogen peroxide and electron-beam irradiation treatment for removal and inactivation of viruses in equine-derived xenografts | |
| BRPI0621074B1 (pt) | método de inativação viral através de aquecimento a seco | |
| PL174098B1 (pl) | Kompozycja stabilizująca osocze krwi podczas pasteryzacji i sposób pasteryzacji osocza krwi | |
| JP2879427B2 (ja) | ウイルスおよびバクテリア汚染物の熱的不活性化中の生物学的および製薬的生成物の安定化 | |
| MX2014005006A (es) | Metodo para preparar solucion de fibrinogeno altamente concentrada y metodo para preparar sellador de fibrina al usar la misma. | |
| WO2001087357A2 (en) | Gamma irradiation of protein-based pharmaceutical products | |
| US20180000759A1 (en) | Lyophilized mesna compositions | |
| CN1599616A (zh) | 贮存稳定的人纤维蛋白原溶液 | |
| FI96918C (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
| JPS6210019A (ja) | 人血液凝固第９因子含有製剤の加熱処理方法 | |
| HUP0001841A2 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition | |
| Zhou et al. | Carrier and Liquid Heat Inactivation of Poliovirus and | |
| Cantera | Formulation challenges in Lyophilized products | |
| CZ20001909A3 (cs) | Použití tranexamové kyseliny pro výrobu prostředku lidského fibrinogenu a lidský fíbrinogenový prostředek | |
| Geiss et al. | Bleeding after cardiovascular surgery caused by detergent residues in laparotomy sponges | |
| IE55182B1 (en) | Heat treatment of plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2006, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2610 DE 12-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |